APOTHEEK OPSOMER
ActiveAPOTHEEK OPSOMER has been active since 2001 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €1.04M and a net result of €28k. Equity is growing by ~2.5% per year across the filed fiscal years. Its solvency ranks better than 92% of 10345 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.5% (very low).
Checked score
Score 2025
80
/ 100
Excellent
The score weighs solvency, liquidity, profitability and financial development. Bankruptcy probability contributes 35%. Every signal that weighs is under Signals.
Axes · tick = 2024
Profitability72▼-4
Solvency100=
Growth52=
Track record100
Bankruptcy probability, 12 months
0.5%
Very low
0%0.5%1.5%4%10%≥ 25%
Credit up to €80k at 30 days acceptable
Liquidity ample (current ratio 4.9 against 3.82 in 2024; short-term debt: 11.6% and cash: 16.1% of total assets), and 14.4% of the assets are financed with debt.
Credit advice for your own amount and term
Signals
Six signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 47
Relative position
BE, all sectors
reference
Sector 47
higher
← fewer bankruptcies
more bankruptcies →
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation dateAge against the risk zone
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
85.6%
Return on assets
2.3%
Age of the figures
15 mo
neutral · Latest accounts filed on time
The financial year that closed on 30-06-2025 was due by 31-01-2026 and was filed on 23-01-2026, 8 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
8 d early
2024
32 d early
2023
28 d early
2022
4 d early
2021
6 d early
2020
51 d early
2019
17 d early
← before the deadline
after the deadline →
neutral · The next deadline is still running
The next financial year closes on 30-06-2026 and is due by 31-01-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
30-06-2026 close22-09-2026 today31-01-2027 deadline
Financials · fiscal year 2025, abbreviated schema
Equity
€1.04M▲ 2.7%
2024 · €1.01M
2019: €893k
2020: €938k
2021: €966k
2022: €871k
2023: €937k
2024: €1.01M
2019 → 2025
Total assets
€1.22M▼ 5.4%
2024 · €1.28M
2019: €1.68M
2020: €1.55M
2021: €1.50M
2022: €1.51M
2023: €1.28M
2024: €1.28M
2019 → 2025
Net result
€28k▼ 62.9%
2024 · €75k
2019: €92k
2020: €45k
2021: €54k
2022: €335k
2023: €72k
2024: €75k
2019 → 2025
Working capital
€548k▲ 4.0%
2024 · €527k
2019: €138k
2020: €142k
2021: €207k
2022: €396k
2023: €487k
2024: €527k
2019 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line20212022202320242025Trend
Equity€966k-€871k▼ 9.8%€937k▲ 7.6%€1.01M▲ 8.0%€1.04M▲ 2.7%
Operating result€76k-€450k▲ 493%€101k▼ 77.7%€90k▼ 10.2%€28k▼ 68.5%
Net result€54k-€335k▲ 519%€72k▼ 78.5%€75k▲ 3.6%€28k▼ 62.9%
Turnover and EBIT margin not published: the abbreviated schema does not require them.
Result per fiscal year
Operating resultNet result
The operating result has fallen three years in a row; 2025 is 69% below 2024 and is the lowest result in the available series.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €1.22M
Fixed assets
€527k▼ 7.5%
Current assets
€688k▼ 3.6%
Equity and liabilities €1.22M
Equity
€1.04M▲ 2.7%
Debt
€175k▼ 35.5%
The debt ratio falls from 21.2% to 14.4%. Equity is higher and debt is lower.
Key figures and ratios
EBITDA
€76k▼
2024 · €139k
Cash flow
€76k▼
2024 · €124k
Solvency
85.6%▲
2024 · 78.8%
Current ratio
4.90▲
2024 · 3.82
Quick ratio
3.46▲
2024 · 2.75
Debt / equity
0.17▼
2024 · 0.27
ROE
2.7%▼
2024 · 7.4%
ROA
2.3%▼
2024 · 5.8%
Interest coverage
17.57▼
2024 · 55.27
Debt
€175k▼
2024 · €272k
Debt ≤ 1 year
€140k▼
2024 · €187k
Debt > 1 year
€34k▼
2024 · €83k
Income taxes
€10k▼
2024 · €22k
Staff costs
€137k▼
2024 · €183k
Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.
Filed annual accounts
As filed with the NBB · 2025 against 2024
Balance sheet
Code20242025
Assets
Total assets20/58€1.28M€1.22M▼
Fixed assets21/28€569k€527k▼
Tangible fixed assets22/27€569k€527k▼
Land and buildings22€545k€507k▼
Plant, machinery and equipment23€25k€15k▼
Furniture and vehicles24-€5k
Current assets29/58€714k€688k▼
Stocks and contracts in progress3€199k€203k▲
Stocks30/36€199k€203k▲
Amounts receivable within one year40/41€234k€270k▲
Trade receivables40€81k€63k▼
Other amounts receivable41€153k€207k▲
Cash at bank and in hand54/58€270k€196k▼
Deferred charges and accrued income490/1€11k€20k▲
Equity and liabilities
Total equity and liabilities10/49€1.28M€1.22M▼
Equity10/15€1.01M€1.04M▲
Contributions10/11€30k€30k=
Reserves13€982k€1.01M▲
Tax-exempt reserves132€182k€182k=
Distributable reserves133€800k€828k▲
Amounts payable17/49€272k€175k▼
Amounts payable after more than one year17€83k€34k▼
Financial debts170/4€83k€34k▼
Amounts payable within one year42/48€187k€140k▼
Current portion of amounts payable after more than one year42€49k€48k▼
Trade debts44€98k€64k▼
Suppliers440/4€98k€64k▼
Advances received on contracts in progress46€1k-
Taxes, remuneration and social security45€39k€28k▼
Taxes450/3€9k€2k▼
Remuneration and social security454/9€29k€26k▼
Accrued charges and deferred income492/3€2k€499▼
Income statement
Code20242025
Remuneration, social security and pensions62€183k€137k▼
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€49k€48k▼
Other operating charges640/8€2k€3k▲
Gross operating margin9900€325k€216k▼
Operating profit (loss)9901€90k€28k▼
Financial income75/76B€9k€13k▲
Recurring financial income75€9k€13k▲
Financial charges65/66B€3k€4k▲
Recurring financial charges65€3k€4k▲
Profit (loss) for the period before taxes9903€97k€37k▼
Income taxes67/77€22k€10k▼
Profit (loss) for the period9904€75k€28k▼
Profit (loss) for the period to be appropriated9905€75k€28k▼
Appropriation of the result
Profit (loss) to be appropriated9906€75k€28k▼
Transfer to equity691/2€75k€28k▼
To other reserves6921€75k€28k▼
Social balance
Average headcount (FTE)90873.22.3▼
The notes to these accounts (10 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
23-01
NBB filing
Annual accounts filed
fiscal year 2025 · abbreviated schema
2025
30-06
Financial
Weakest financial yearnet €28k ▼62.9%
Net result drops to €28k, the lowest in the series.
2024
30-12
NBB filing
Annual accounts filed
fiscal year 2024 · abbreviated schema
30-06
Financial
Equity above €1MEq €1.01M ▲8%
6 profitable years in a row build equity to €1.01M.
03-01
NBB filing
Annual accounts filed
fiscal year 2023 · abbreviated schema
2023
30-06
Financial
Liquidity doublescurrent ratio 3.81
Current ratio from 1.88 to 3.81; short-term debt falls from €449k to €173k.
27-01
NBB filing
Annual accounts filed
fiscal year 2022 · abbreviated schema
2022
30-06
Financial
Highest result since 2019net €335k ▲519%
Operating result €450k, net result €335k, both a record.
25-01
NBB filing
Annual accounts filed
fiscal year 2021 · abbreviated schema
2020
11-12
NBB filing
Annual accounts filed
fiscal year 2020 · abbreviated schema
14-01
NBB filing
Annual accounts filed
fiscal year 2019 · abbreviated schema
2018
19-12
NBB filing
Annual accounts filed
fiscal year 2018 · abbreviated schema
15-01
NBB filing
Annual accounts filed
fiscal year 2017 · abbreviated schema
2017
13-01
NBB filing
Annual accounts filed
fiscal year 2016 · abbreviated schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
3 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Poperinge · 1 establishment unit since 2001
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Garenstraat 178970 PoperingeGround area
359 m²
Building footprint
362 m²
Volume, LiDAR
2,288 m³
Parcel 33021F1636/00A000, Flanders · tallest building 12.0 m, ±2 floors. Linked by address, not a title deed.
1 establishment unit
Garenstraat 17, 8970 Poperinge
since 20012.095.191.189
1 parcel
Flanders
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 33021F1636/00A000 | Flanders | 359 m² | 1 · 362 m² | 12.0 m · 2 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Public money · subsidies and aid
Flemish government
2022 to 2025 · 3 entries · 169 EUR awarded · 222 EUR paid| Year | Entries | awarded | paid |
|---|---|---|---|
| 2025 | 1 | 36 EUR | 36 EUR |
| 2023 | 1 | 0 EUR | 53 EUR |
| 2022 | 1 | 133 EUR | 133 EUR |
Schemes
Subsidie voor opleiding en advies voor kmo's en zelfstandigen (kmo-portefeuille)
Recognitions · licences · registrations
Food safety, FASFC
1 sitePoperinge2.095.191.189
Similar companies · same sector, comparable size
Pharma2Care
BE 0427.391.896
Zuienkerke · Eq €1.04M
FARMA SPRUYT
BE 0460.739.013
Kortenberg · Eq €1.04M
Apotheek Vanoost
BE 0897.372.536
Aalst · Eq €1.04M
PHARMACIE MOLITOR-MEIRLAEN
BE 0876.905.635
Viroinval · Eq €1.04M
APOTEEK SERMEUS
BE 0429.117.409
Zemst · Eq €1.04M
Of 5,222 companies in sector 47730 we hold annual accounts for 3,861. 2,982 are within a factor 10 of this equity.See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company
Founded31-05-2001
Fiscal year end30-06
Activities, NACEBEL
47730Retail sale of pharmaceutical products
52310
Sources
Crossroads Bank for EnterprisesNational Bank · 24 filingsAddress and cadastre registers
Data from official sources, last processed on 22-09-2026. Scores and ratios are computed by Checked and are not a credit decision.
Contact details
1 entryE-mail:frank.opsomer@dynaphar.be